Treprostinil
Sponsors
United Therapeutics Corp., United Therapeutics, Rajan Saggar, University Hospital, Grenoble, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Conditions
Congenital Heart DiseaseDelayed Graft FunctionFibrotic Lung DiseaseHealthyHealthy AdultsIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseIschemia Reperfusion Injury
Phase 1
Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers
CompletedNCT01082484
Start: 2010-01-31End: 2011-01-31Target: 20Updated: 2011-10-06
Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation
CompletedNCT01481974
Start: 2012-12-31End: 2019-11-24Updated: 2023-12-15
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
CompletedNCT02770521
Start: 2016-05-31End: 2016-07-31Updated: 2020-06-04
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
RecruitingNCT04005469
Start: 2020-11-13End: 2026-06-30Target: 20Updated: 2023-07-20
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
CompletedNCT04675944
Start: 2018-02-28End: 2018-05-25Updated: 2020-12-19
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
CompletedNCT05067270
Start: 2021-10-22End: 2021-12-06Updated: 2023-10-04
Phase 2
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
CompletedNCT00705133
Start: 2008-07-31End: 2011-04-30Updated: 2020-09-09
Acute Effects of Inhaled Treprostinil in Fontan Patients
TerminatedNCT02769624
Start: 2017-02-21End: 2018-09-21Updated: 2020-07-29
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
CompletedNCT05564637
Start: 2023-03-13End: 2024-10-30Updated: 2025-12-03
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
Not yet recruitingNCT07177703
Start: 2025-10-31End: 2027-12-31Target: 32Updated: 2025-09-17
Phase 3
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease
Active, not recruitingCTIS2023-504471-25-00
Start: 2024-03-01Target: 319Updated: 2025-12-10
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
CompletedCTIS2024-514761-19-00
Start: 2023-01-25End: 2025-06-25Target: 382Updated: 2025-01-31
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
RecruitingCTIS2023-504904-26-00
Start: 2025-04-07Target: 215Updated: 2025-12-02
Phase 4
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
TerminatedNCT00439946
Start: 2007-02-28End: 2011-03-31Updated: 2024-01-03
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
CompletedNCT01268553
Start: 2010-08-31End: 2016-10-05Updated: 2017-09-01
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
NCT03835676
Start: 2019-05-01End: 2025-12-01Target: 30Updated: 2022-12-15
Unknown Phase
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
CompletedNCT01028651
Start: 2011-01-31End: 2013-04-30Updated: 2017-02-24
Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
TerminatedNCT02498444
Start: 2015-09-30End: 2020-12-31Updated: 2022-03-31
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
CompletedNCT03888365
Start: 2019-04-01End: 2019-09-19Updated: 2021-03-16
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
Not yet recruitingNCT06603285
Start: 2025-10-16End: 2029-12-31Target: 20Updated: 2025-08-15